Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.

BMC gastroenterology - 27 Feb 2013

Donada Marisa, Bonin Serena, Barbazza Renzo, Pettirosso Daniel, Stanta Giorgio

Abstract excerpt

BACKGROUND: There is uncertainty on the benefit of adjuvant chemotherapy in patients with stage II colorectal cancers. The aim of this study is to investigate the combined role of clinical, pathological and molecular parameters to identify those stage II patients who better benefit from adjuvant therapy. METHODS: We examined 120 stage II colon cancer patients. Of these, 60 patients received adjuvant 5-FU...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to CD8 Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Colectomy

Share to Disease Management

Share to DNA Mismatch Repair

Share to Fluorouracil

Share to Thymidylate Synthase

Source

Open in PubMed Open full text

Identifiers

PMID: 23446022
DOI: 10.1186/1471-230X-13-36
PMCID: PMC3599045

Genes

TYMS
BRAF
CTNNB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.PMID 23446022Read ↗

Prognostic and predictive significance of MSI in stages II/III colon cancer.Semantic proximity Read ↗

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy.Semantic proximity Read ↗

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.Semantic proximity Read ↗

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.Semantic proximity Read ↗

Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.Semantic proximity Read ↗

KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Development and validation of a prognostic nomogram for patients with stage II colon mucinous adenocarcinomaSemantic proximity Read ↗

Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer.Semantic proximity Read ↗

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.Semantic proximity Read ↗

Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population‐based studySemantic proximity Read ↗

Development of a Clinically Feasible Molecular Assay to Predict Recurrence of Stage II Colon CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.